Modern Pediatrics. Ukraine. (2022). 2(122): 15-20. doi 10.15574/SP.2022.122.15
Abaturov O. E., Tokarieva N. M., Lykova A. E., Krivusha O. L.
Dnipro State Medical University, Ukraine

For citation: Abaturov OE, Tokarieva NM, Lykova AE, Krivusha OL. (2022). Dynamics of gene expression of T-cells and interleukin transcription factors on the background of probiotic therapy of chronic gastroduodenitis in children. Modern Pediatrics. Ukraine. 15-20. doi 10.15574/SP.2022.122.15.
Article received: Nov 09, 2021. Accepted for publication: Mar 06, 2022.

Chronic gastroduodenitis (HGD) in children is one of the most common diseases of the digestive tract in children, the treatment of which needs to be improved.
Purpose – to study the effectiveness of Lactobacillus rhamnosus GG ATCC 53103 (LGG) in the treatment of children with chronic gastroduodenitis and the effect of treatment on the expression of pro- and anti-inflammatory cytokines and T-lymphocyte transcription factors in the buccal mucosa.
Materials and methods. We examined 39 children with chronic gastroduodenitis aged 10-14 years, of which 2 comparison groups were formed. The main group (n=21) included patients for whose treatment, in addition to traditional therapy, a probiotic drug was containing 5×10⁹ lyophilized viable bacteria LGG. The control group (n=18) was represented by patients receiving only traditional therapy. The duration of treatment with probiotic LGG was 14 days. To prove the effectiveness of LGG in therapy, the level of mRNA expression of transcription factors (Tbet, RORyt, FOXP3) of T cells and interleukins (IL-1β, IL-17α, IL-10) was determined by polymerase chain reaction with reverse transcription.
Results. The period of CGD exacerbation was characterized by an increase in the expression level of mRNA of the RORyt transcription factor of Th₁₇-cells and mRNA of IL-1β, IL-17α in the buccal mucosa. After standard therapy in children with CHD, there was a significant increase in the activity of mRNA expression of the transcription factor Tbet of Th₁-cells and a decrease in the activity of mRNA expression of the RORyt of transcription factor Th₁₇-cells. After treatment with combination therapy using a probiotic preparation containing LGG, there was also a decrease in the activity of mRNA expression of the RORyt transcription factor of Th₁₇-cells, but in contrast to children who received standard therapy, there was a low level of mRNA of the transcription factor Tbet of Th₁-cells and mRNA IL-17α; in combination with an increased level of mRNA of the FOXP3 transcription factor of Treg-cells.
Conclusions. The appointment of a combination therapy using a probiotic preparation containing Lactobacillus rhamnosus GG in children with chronic gastroduodenitis contributes to the rapid regression of the clinical manifestations of pain, dyspeptic syndromes. The administration of LGG leads to a more rapid decrease in the level of expression of the IL-17 genes due to an increase in the activity of mRNA expression of the FOXP3 of Treg-cells.
The research was carried out in accordance with the principles of the Helsinki declaration. The study protocol was approved by the Local ethics committee of the participating institution. The informed consent of the patient was obtained for conducting the studies.
No conflict of interest was declared by the authors.
Key words: chronic gastroduodenitis, children, transcription factors, interleukins, probiotic therapy, Lactobacillus rhamnosus GG.

REFERENCES

1. Abaturov AYe, Kaidashev IP, Nikulina AO, Tokarieva NM, Kryvusha OL, Lykova AE. (2020). Anti-inflammatory effects of probiotic therapy of chronic gastroduodenitis in children. Child's Health. 5 (15): 17-23. https://doi.org/10.22141/2224-0551.15.5.2020.211437

2. Abаturov АYe, Gerasymenko ON, Zavgorodnyaya NYu. (2014). Hronicheskie CagA(+) Helicobacter Pylori-associirovannye gastrity u detej. Chronic CagA(+) Helicobacter Pylori-associated gastritis in children. Kharkov: САМ. 412.

3. Adamsson J, Ottsjö LS, Lundin SB, Svennerholm AM, Raghavan S. (2017, Nov). Gastric expression of IL-17α and IFNγ in Helicobacter pylori infected individuals is related to symptoms. Cytokine. 99: 30-34. Epub 2017 Jul 3. https://doi.org/10.1016/j.cyto.2017.06.013; PMid:28683359

4. Alvarez F, Al-Aubodah TA, Yang YH, Piccirillo CA. (2020, Aug). Mechanisms of TREG cell adaptation to inflammation. J Leukoc Biol. 108 (2): 559-571. Epub 2020 Mar 23. https://doi.org/10.1002/JLB.1MR0120-196R; PMid:32202345

5. Anfylova MH, Vostrykov PP. (2020). The prevalence of concomitant pathology in children with chronic gastroduodenitis and Helicobacter pylori infection. In WEEK OF SCIENCE – 2020. Materials of the International Youth Forum: 275-276.

6. Antypkin YuH, Volosovets OP, Maidannyk VH, Berezenko VS, Moiseienko RO, Vyhovska OV, Kryvopustov SP, Zabolotko VM, Ariaiev ML, Abaturov OYe. (2018). The state of health of children – the future of countries (part 1). Child's Health. 13 (1): 1-11.

7. Arachchi PS, Fernando N, Weerasekera MM, Senevirathna B, Weerasekera DD, Gunasekara CP. (2017). Proinflammatory Cytokine IL-17 Shows a Significant Association with Helicobacter pylori Infection and Disease Severity. Gastroenterol Res Pract: 6265150. Epub 2017 Dec 17. https://doi.org/10.1155/2017/6265150; PMid:29391865 PMCid:PMC5748147

8. Attias M, Al-Aubodah T, Piccirillo CA. (2019, Jul). Mechanisms of human FoxP3+ Treg cell development and function in health and disease. Clin Exp Immunol. 197 (1): 36-51. Epub 2019 Apr 1. https://doi.org/10.1111/cei.13290; PMid:30864147 PMCid:PMC6591147

9. Beketova HV. (2012). Chronic gastroduodenitis in children and adolescents: epidemiology, etiology, pathogenesis, diagnosis (part I). Journal «Dytiachyi likar». 6 (19): 20-24.

10. Capurso L. (2019, Mar). Thirty Years of Lactobacillus rhamnosus GG: A Review. J Clin Gastroenterol. 53 (1): S1-S41. https://doi.org/10.1097/MCG.0000000000001170; PMid:30741841

11. Caruso R, Fina D, Paoluzi OA, Del Vecchio Blanco G, Stolfi C, Rizzo A, Caprioli F, Sarra M, Andrei F, Fantini MC, MacDonald TT, Pallone F, Monteleone G. (2008 Feb). IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. Eur J Immunol. 38 (2): 470-478. https://doi.org/10.1002/eji.200737635; PMid:18200634

12. Dewayani A, Fauzia KA, Alfaray RI, Waskito LA, Doohan D, Rezkitha YAA, Abdurachman A, Kobayashi T, I'tishom R, Yamaoka Y, Miftahussurur M. (2021, Apr 28). The Roles of IL-17, IL-21, and IL-23 in the Helicobacter pylori Infection and Gastrointestinal Inflammation: A Review. Toxins (Basel). 13 (5): 315. https://doi.org/10.3390/toxins13050315; PMid:33924897 PMCid:PMC8147029

13. Ji J, Yang H. (2020, Feb 8). Using Probiotics as Supplementation for Helicobacter pylori Antibiotic Therapy. Int J Mol Sci. 21 (3): 1136. https://doi.org/10.3390/ijms21031136; PMid:32046317 PMCid:PMC7037652

14. Jia L, Wu R, Han N, Fu J, Luo Z, Guo L, Su Y, Du J, Liu Y. (2020, Nov 24). Porphyromonas gingivalis and Lactobacillus rhamnosus GG regulate the Th17/Treg balance in colitis via TLR4 and TLR2. Clin Transl Immunology. 9 (11): e1213. https://doi.org/10.1002/cti2.1213; PMid:33282294 PMCid:PMC7685903

15. Keikha M, Karbalaei M. (2021, Oct 20). Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections. BMC Gastroenterol. 21 (1): 388. https://doi.org/10.1186/s12876-021-01977-1; PMid:34670526 PMCid:PMC8527827

16. Marushko YuV, Asonov AO. (2014). Features of chronic gastroduodenitis, morphological changes and gastroprotection in children with zinc deficiency. Child's Health. 4 (55): 7-12.

17. Mišak Z, Hojsak I, Homan M. (2019, Sep). Review: Helicobacter pylori in pediatrics. Helicobacter. 24 (1): e12639. https://doi.org/10.1111/hel.12639; PMid:31486243

18. Molina B, Mastroianni J, Suarez E, Soni B, Forsberg E, Finley K. (2021, Apr 14). Treatment with Bacterial Biologics Promotes Healthy Aging and Traumatic Brain Injury Responses in Adult Drosophila, Modeling the Gut-Brain Axis and Inflammation Responses. Cells. 10 (4): 900. https://doi.org/10.3390/cells10040900; PMid:33919883 PMCid:PMC8070821

19. Poonyam P, Chotivitayatarakorn P, Vilaichone RK. (2019, Sep 1). High Effective of 14-Day High-Dose PPI-Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study. Asian Pac J Cancer Prev. 20 (9): 2859-2864. https://doi.org/10.31557/APJCP.2019.20.9.2859; PMid:31554388 PMCid:PMC6976817

20. Shi CW, Cheng MY, Yang X, Lu YY, Yin HD, Zeng Y, Wang RY, Jiang YL, Yang WT, Wang JZ, Zhao DD, Huang HB, Ye LP, Cao X, Yang GL, Wang CF. (2020, Dec 17). Probiotic Lactobacillus rhamnosus GG Promotes Mouse Gut Microbiota Diversity and T Cell Differentiation. Front Microbiol. 11: 607735. https://doi.org/10.3389/fmicb.2020.607735; PMid:33391230 PMCid:PMC7773731

21. Westerik N, Reid G, Sybesma W, Kort R. (2018, Aug 14). The Probiotic Lactobacillus rhamnosus for Alleviation of Helicobacter pylori-Associated Gastric Pathology in East Africa. Front Microbiol. 9: 1873. https://doi.org/10.3389/fmicb.2018.01873; PMid:30154777 PMCid:PMC6102400